ORLANDO, Fla., Nov. 4 /PRNewswire/ -- Singulex Inc. announced today that its technology will be highlighted in an oral presentation (#3108) at the American Heart Association Scientific Sessions on Wednesday, November 7 at 11:15 a.m. in West F1. The presentation is entitled "Single Molecule Troponin Detection to Assess for Transient Myocardial Ischemia" by Marc Sabatine, M.D., M.P.H. and David Morrow, M.D., M.P.H.
Dr. Sabatine is an associate physician in the Cardiovascular Medicine Division at Brigham and Women's Hospital (BWH), an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and an assistant professor of medicine at Harvard Medical School. Dr. Sabatine's research focuses on the diagnosis and treatment of acute coronary syndromes, with a particular interest in using biomarkers, genetic epidemiology, and proteomics for risk stratification. His research endeavors in those fields are supported by several grants from the National Institutes of Health. Dr. Sabatine has authored over 100 original research articles, reviews, editorials, and book chapters and serves as a manuscript reviewer for several major medical journals. Dr. Sabatine has been awarded a Howard Hughes Medical Institute Research Fellowship, an ACC Cardiology Fellowship, and the ACC Young Investigator Award. He is board certified in Internal Medicine and Cardiology and is a member of the American Heart Association and a Fellow of the American College of Cardiology.
Dr. Morrow is assistant professor of medicine at Harvard Medical School, in the division of cardiovascular medicine at BWH. He was instrumental in the development of the TIMI Biomarker Program at BWH, and his research at TIMI focuses on risk stratification and the management of acute coronary syndromes. Dr. Morrow sits on the National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines Committee on Biochemical Cardiac Markers and leads the clinical section on ACS. He is on the editorial boards of American Heart Journal, Circulation, Clinical Chemistry, and the Journal of the American College of Cardiology and is a Continuing Medical Education editor for Circulation. Dr. Morrow is also the editor of "Cardiovascular Biomarkers: Pathophysiology and Disease Management" and serves on the Program Committee for the American Heart Association Council on Clinical Cardiology. In addition to being a frequent lecturer, Dr. Morrow has more than 100 original reports, reviews, editorials, book chapters, and electronic publications in his areas of expertise.
Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Hayward, California. To learn more about Singulex, please visit us at http://www.singulex.com.
CONTACT: Carolyn Hawley of Porter Novelli Life Sciences, +1-619-849-5375,
email@example.com, for Singulex Inc.
Web site: http://www.singulex.com/